- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03376620
Role of Topical Putrescine (Fibrostat) for Prevention of Hypertrophic Scars in Mammoplasty Patients
Role of Topical Putrescine (Fibrostat) in 10%Urea (TFU) for Prevention of Hypertrophic Scars in Mammoplasty Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
In this study, patients were "randomized" into one of 2 study groups described below. They agreed to being treated on the right side or the left with active agent, while the other side was to receive inactive cream. The active molecule is called Fibrostat or 1,4 diaminobutane and is a naturally occurring inhibitor of scar formation. The inactive jar contains the vehicle alone without Fibrostat.
The patients received both cream types to be applied to the appropriate side assigned by the randomization process, one numbered jar each per breast in the order and amount as explained in detail by the patient educator. The cream was applied daily and in the same order, one jar for the right and the other jar for the left consistently. The randomization was performed at the factory with an assigned number recorded on each jar and the jar contents listed and recorded with its assigned number. Each jar of active cream is randomly assigned with another jar of inactive cream to form a pair which were both given to the patient. The cream in both jars looks and smells the same. Neither the patient nor the study doctor knew which breast as receiving the active agent. In an emergency, this information was to be made available.
Participation in the study was for 12 weeks. the patients were seen for photos and scar testing using a painless surface testing device called a Rex® durometer at 1, 3, 6, and 12 weeks post op.
The researcher could decide to take patients off this study if a patient were to develop a rash during the run-in period of 1 week from the cream on either side.
The patients could stop participating at any time. However, this was usually accompanied by a valid reason such as lack of transportation to regular follow up appointments. No serious effects were seen and the only patients to stop participation in the study except 1 which was lost to follow-up could be accounted for. The results were revealed to patients at the completion of the 12 week trial.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria: Undergoing breast reduction surgery -
Exclusion Criteria: Not pregnant or lactating
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Sham Comparator: 10% Urea cream
Opposite breast scars treated OD at hs simultaneously using sham 10% Urea cream
|
Daily application to surgical breast scars of 10% Urea cream on the sham side
|
Active Comparator: Active cream with 1,4 diaminobutane
Other breast scar treated daily with active cream with 1,4 diaminobutane topically OD at hs
|
Daily application to surgical breast scars of 1,4 diaminobutane on the active side
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duredness of scar at post treatment time frame for active versus control breast
Time Frame: 12 weeks
|
Surface deformational force in grams of scar tissue in each of the treated breasts
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Observer Objective Scar Assessment Scale ratings
Time Frame: at least one year post operatively
|
Validated scale of scar outcome based on seven parameters graded on a scale of 1-10 ranked lowest to highest in severity.
Patient was the "observer" in this study making subjective parameters listed such as pain and itch a direct patient correlate rather than one recorded by a second-person observation.
|
at least one year post operatively
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- B2008:134
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertrophic Scar
-
Iran University of Medical SciencesRecruitingDry Needling | Scar Tissue | Hypertrophic Scar | Hypertrophic Surgical Scar | Hypertrophic Scar of Upper Arm (Disorder)United States, Iran, Islamic Republic of
-
University of PittsburghUnited States Department of DefenseTerminatedBurn Scar | Restrictive Scar Contracture | Restrictive Hypertrophic Scar | Burn Scar ContracturesUnited States
-
Nova Scotia Health AuthorityRecruiting
-
Henry Ford Health SystemActive, not recruitingScar | Hypertrophic ScarUnited States
-
Universiti Kebangsaan Malaysia Medical CentreCompletedKeloid Scar Following Surgery | Caesarean Wound | Hypertrophic Surgical ScarMalaysia
-
Medstar Health Research InstituteCompletedBurn Scar | Hyperpigmentation | Hypertrophic Scar | Hypopigmented ScarUnited States
-
PfizerTerminatedHypertrophic Scars Resulting From Prior Breast Scar Revision SurgeryUnited States
-
Dr.dr.Irma Bernadette, SpKK (K)Not yet recruitingBurn Scar | Scars, HypertrophicIndonesia
-
Seoul National University HospitalCompletedHypertrophic Surgical ScarKorea, Republic of
-
Kaohsiung Medical UniversityUnknown
Clinical Trials on 10% Urea cream
-
Taipei Veterans General Hospital, TaiwanCompletedHepatocellular Carcinoma
-
University of BrasiliaUniversity of WashingtonCompletedRadiodermatitisBrazil
-
Mahidol UniversitySiriraj HospitalRecruiting
-
Korea University Guro HospitalHanmi Pharmaceutical Company LimitedCompletedHepatocellular CarcinomaKorea, Republic of
-
University of BrasiliaCompletedRadiodermatitisBrazil
-
Galderma R&DCompleted
-
Universidad Complutense de MadridCompleted
-
University of BrasiliaUniversity of Washington; Conselho Nacional de Desenvolvimento Científico e...Unknown
-
West German Center of Diabetes and HealthBionatural GmbHCompleted
-
Galderma R&DCompleted